Phase 3 randomized study of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.

Affiliation auteurs!!!! Error affiliation !!!!
TitrePhase 3 randomized study of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.
Type de publicationJournal Article
Year of Publication2019
AuteursMoreau P, Attal M, Hulin C, Bene M-C, Broijl A, Caillot D, Delforge M, Dejoie T, Facon T, Lambert J, Leleu X, Macro M, Perrot A, Zweegman S, Ahmadi T, Chiu C, Pei L, Vermeulen J, Avet-Loiseau H, Sonneveld P
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume37
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X